ArticleHeliyon2022
On-chip testing of a carbon-based platform for electro-adsorption of glutamate.
Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 5 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is known that excessive concentrations of glutamate in the brain can cause neurotoxicity. A common approach to neutralizing this phenomenon is the use of suppressant drugs. However, excessive dependence on suppressant drugs could potentially lead to adversarial side effects, such as drug addiction. Here, we propose an alternative approach to this problem by controlling excessive amounts of glutamate ions through carbon-based, neural implant-mediated uptake. In this study, we introduce a microfluidic system that enables us to emulate the uptake of glutamate into the carbon matrix. The uptake is controlled using electrical pulses to incorporate glutamate ions into the carbon matrix through electro-adsorption. The effect of electric potential on glutamate ion uptake to control the amount of glutamate released into the microfluidic system was observed. The glutamate concentration was measured using a Ultra Violet-Visible spectrophotometer. The current setup demonstrated that a low pulsatile electric potential (0.5-1.5 V) was able to effectively govern the uptake of glutamate ions. The stimulated carbon matrix was able to decrease glutamate concentration by up to 40%. Furthermore, our study shows that these "entrapped" glutamate molecules can be effectively released upon electrical stimulation, thereby reversing the carbon electrical charge through a process called reverse uptake. A release model was used to study the profile of glutamate release from the carbon matrix at a potential of 0-1.5 V. This study showed that a burst release of glutamate was evident at an applied voltage higher than 0.5 V. Ultimately, the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) test for cytotoxicity indicated a cell viability of more than 80% for the carbon matrix. This test demonstrates that the carbon matrix can support the proliferation of cells and has a nontoxic composition; thus, it could be accepted as a candidate material for use as neural implants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.